MIME-Version: 1.0
Date: Tue, 28 Sep 2021 09:24:53 +0000
Message-ID: <CACNgykMd06_8T=LBrb+Q19Fh2Q80fTJ7QQceabjTkE3ZPnMM8Q@mail.gmail.com>
Subject: On Bala's recommentation
From: Josh Klein <josh@josh.is>
To: Sigurbjorg Jonsdottir <silla@retinarisk.com>
Content-Type: multipart/alternative; boundary="000000000000678c6c05cd0ac952"

--000000000000678c6c05cd0ac952
Content-Type: text/plain; charset="UTF-8"
Content-Transfer-Encoding: quoted-printable

Bala mentioned you're developing analytics for other risk vectors, such as
heart disease. Do you have an updated deck I could review? I'm pitching a
CGM-based study to J&J and Novo Nordisk and would love to know if there's
any overlap!

All best,
Josh

=E1=90=A7

--000000000000678c6c05cd0ac952
Content-Type: text/html; charset="UTF-8"
Content-Transfer-Encoding: quoted-printable

<div dir=3D"ltr">Bala mentioned you&#39;re developing=C2=A0analytics for ot=
her risk vectors, such as heart disease. Do you have an updated deck I coul=
d review? I&#39;m pitching a CGM-based study to J&amp;J and Novo Nordisk an=
d would love=C2=A0to know if there&#39;s any overlap!<div><br></div><div>Al=
l best,</div><div>Josh</div><div><br></div></div><div hspace=3D"streak-pt-m=
ark" style=3D"max-height:1px"><img alt=3D"" style=3D"width:0px;max-height:0=
px;overflow:hidden" src=3D"https://mailfoogae.appspot.com/t?sender=3Daam9za=
EBqb3NoLmlz&amp;type=3Dzerocontent&amp;guid=3Db3ee7338-b552-40aa-964e-cae1e=
304e614"><font color=3D"#ffffff" size=3D"1">=E1=90=A7</font></div>

--000000000000678c6c05cd0ac952--